Mitsubishi UFJ Asset Management
ABCL icon

Mitsubishi UFJ Asset Management’s AbCellera Biologics ABCL Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37,154
Closed -$168K – 1572
2024
Q1 		$168K Sell
37,154
-1,701
-4% -$8.68K ﹤0.01% 974
2023
Q4 		$221K Buy
38,855
+4,641
+14% +$21.5K ﹤0.01% 997
2023
Q3 		$157K Hold
34,214
– – ﹤0.01% 1044
2023
Q2 		$221K Buy
34,214
+19,083
+126% +$130K ﹤0.01% 1024
2023
Q1 		$114K Buy
15,131
+2,140
+16% +$19.4K ﹤0.01% 1081
2022
Q4 		$123K Sell
12,991
-8,875
-41% -$103K ﹤0.01% 1073
2022
Q3 		$216K Buy
21,866
+9
+0% +$99 ﹤0.01% 1014
2022
Q2 		$233K Buy
21,857
+5,849
+37% +$49.5K ﹤0.01% 1027
2022
Q1 		$156K Buy
16,008
+1,854
+13% +$17.6K ﹤0.01% 1089
2021
Q4 		$200K Buy
14,154
+7,096
+101% +$108K ﹤0.01% 1084
2021
Q3 		$141K Hold
7,058
– – ﹤0.01% 1092
2021
Q2 		$155K Buy
+7,058
New +$195K ﹤0.01% 1104

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Mitsubishi UFJ Asset Management's ABCL Position: Q2 2024 in Review

Mitsubishi UFJ Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 37,154 shares — an estimated $168K sold.

Mitsubishi UFJ Asset Management first reported a position in ABCL in Q2 2021 and held it in 12 quarters. The position peaked at $233K in Q2 2022. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Mitsubishi UFJ Asset Management reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 37,154 AbCellera Biologics shares in Q2 2024, an estimated $168K.
  • Mitsubishi UFJ Asset Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 12 quarters.
  • Mitsubishi UFJ Asset Management's AbCellera Biologics position peaked at $233K in Q2 2022.
  • 147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.